title: [Clinical study on single-dose rhG-CSF combined with chemotherapy in autologous peripheral blood stem cell transplantation].
abstract: OBJECTIVE
  This study was designed to evaluate the effectiveness of high-dose chemotherapy plus single daily dose of 250 micrograms/d rhG-CSF(lenograstim) in autologous peripheral blood stem cells mobilization and hematopoietic reconstitution after transplantation.
  
  
  METHODS
  The study included a group of 55 consecutive patients with hematological malignancies (28 cases of acute myelogenous leukemia, 9 cases of acute lymphoblastic leukemia, 14 cases of non-Hodgkin's lymphoma, 4 cases of other disease) from October 1999 to December 2001 undergoing either EA or other intensive chemotherapies as CTX, G-CSF mobilization began from the day when the WBC count reached nadir until the day of apheresis, then after stem cell reinfusion G-CSF support was given on day +3 until neutrophil recovery. The dose of G-CSF both in mobilization and recovery support was 250 micrograms/d s.c. despite the body weight of patients.
  
  
  RESULTS
  The average time of G-CSF administrating as a mobilizing reagent was 7.12 days(range 3-14 days), and the mean time of interval from the beginning of chemotherapy to apheresis was 18.08 +/- 3.63 days. All patients need an average of 1.3 times for apheresis. The median mononuclear cell and CD34+ cell yield were 4.09 x 10(8)/kg and 8.5 x 10(6)/kg, respectively. G-CSF was used after transplantation for a median time of 8 days(range 4-19). All patients achieved an ANC > 0.5 x 10(9)/L after a median of 10.5 days (range 8-26). No severe toxic reaction was observed.
  
  
  CONCLUSIONS
  We concluded that chemotherapy plus rhG-CSF(lenograstim) given in the single dose fashion can be used in both mobilizing and post transplantation setting with satisfying outcome.
authors.affiliation: tian@fimmu.com
authors.forename: Hong
authors.initials: H
authors.lastname: Tian
authors.forename: Shu-yun
authors.initials: SY
authors.lastname: Zhou
mesh_terms: D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000276:immunology; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor